Life Sciences Archive » July, 2026

Life Sciences - July, 2026

304 articles

• Mich. Justices' Ruling Will Allow Eli Lilly Price-Fixing Probe
• Appeals Courts Upheld Similar E-Cig Regs, Pa. Tells Court
• Lab, Ex-CEO, Fla. Resident To Pay $36M Over Kickback Claims
• Fed. Circ. Says Leica's Filtered Light Skirts U. Mich. Patent
• TRESemme Hair Loss Suit Filed 2 Years Too Late, Judge Finds
• Thermo Fisher Says Ex-VP Took 'Know-How' To Rival
• End In Sight For Ovarian Cancer Patients With $5.5B+ J&J Deal
• Patent Eligibility Bulletin: New USPTO Guidance And AI Risks
• J&J's $25M Talc Appeal Can Advance, Conn. Panel Rules
• A Shift In How Policymakers Are Approaching PBM Regulation
• AI Drugmaker Investors Seek Final OK For $9.75M Fraud Deal
• No Standing For NY 'Aid-In-Dying' Law Challenge, Judge Rules
• Just For Men Maker Says Insurers Must Cover Injury Deals
• Insulet Urges Full Fed. Circ. To Revive $59M Trade Secret Win
• 9th Circ. Reverses Hologenix CEO's Tortious Interference Loss
• NC, Green Groups Call EPA-Chemours PFAS Deal Too Lenient
• Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
• CBP Outlines Rates, Classifications For Pharma Tariffs
• Albertsons Can't Nix 14 Years Of Opioid Claims At Wash. Trial
• Squires Erases PTAB Ax Of Dermatology IP Upheld At ITC
• Curium, Sazerac And Stripe Pursue Megadeals, And More
• 2nd Circ. Revives Decongestant 'Maximum Strength' Claims
• Covidien Hid Mesh Risks, Bellwether Jury Told As Trial Ends
• 11th Circ. Opioid Appeal May Shift Public Nuisance Coverage
• States Should Reconsider Forced PBM Divestiture Laws
• Squires Grants 6 Patent Petitions, Denies 4 In New Order
• J&J Pans Talc Claimant's 'Absurd' Bid To Nix $25M Appeal
• Teaching SEC Investigations Makes Me A Better Lawyer
• Pa. Paraquat, Gov. Shapiro's Neighbors: A Midyear Report
• 2 Traders Admit Guilt In Stolen BigLaw Info Scheme
• Monsanto Ruling Bolsters Generic Drug Labeling Preemption
• Albertsons Pharmacy Work Was 'House Of Cards,' Judge Told
• 2nd Circ. Backs Ex-Shkreli Atty's 401(k) Restitution Deal
• Novo Faces Narrowed Investor Suit Over Obesity Drug Claims
• Depo-Provera MDL Gets New Lead Plaintiffs After Settlement
• Curaleaf Says Pot Suit Is Long On Length But Not Substance
• FTC Says Hims & Hers Shares Health Data, Misleads Users
• Colo. Hospital Patients In Gender Care Suit Seek Class Cert.
• 9th Circ. Revives Biotech Worker's Pension Plan Suit
• Planned Parenthood Lab's $6.1M Breach Deal Gets Initial OK
• Health Economist's Report Cleared For Generic-Drug MDL
• J&J Says Cancer Drug Study Sinks Bayer's False Ad Claims
• Patent Eligibility Reforms Keep Chasing The Wrong Fixes
• Attys Secure $15M Fees In Abbott Formula Shareholder Suit
• No COVID Immunity For Mich. Hospitals In Malpractice Revival
• Where The Justices Aligned In Appellate Authority Ruling
• NC Woman Drops Bone Cement Suit Against Zimmer Biomet
• 340B Appellate Cases To Watch In The 2nd Half Of 2026
• Teva Can't 'Literally Whine' Of Being Held To DOJ Admissions
• Goodwin Grows Life Sciences Group With San Diego IP Hire
• Trader In BigLaw Deal-Tipping Scheme To Plead Guilty
• Albertsons Opioid Trial Told Of Needles, ODs In Library
• J&J, Ovarian Cancer Talc Claimants Unveil $5.5B Global Deal
• Union Funds Seek Final OK For $180M In Opioid Deals
• Taco Bell, Taylor Farms Hit With Another Cyclospora Suit
• Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case
• Hygiene Co. Can't Fight FTC's Need To Back Up COVID Claims
• Cooley Owes $25.4M Judgment To NJ Biotech Co. Founder
• Verano Unit Accused Of Infringing Cannabis Extraction Patent
• Quinn Emanuel's Ethics Training 'Promising,' Judge Says
• Health Data Co. Inks $4.8M Settlement To End Investor Suit
• Yale, Biohaven Win $4M In Biotech Trade Secret Trial
• Protecting Biotech Innovation In The Platform Knowledge Era
• Judges On AI: Examining Administrative, Organizational Uses
• AbbVie Seeks Block On Alkem Generic Constipation Drug
• Regeneron Says Drug Approval Irrelevant In Antitrust Case
• Hemp Co. Says DEA Defied Farm Bill By Banning HHC
• Catching Up With Delaware's Chancery Court
• Stewart Leaving USPTO This Week For Private Sector Job
• Cannabis In The Courts: A Midyear Litigation Review
• Alkegen Files Ch. 11 In Texas To Shed $3.1B In Debt
• Arnold & Porter Hires King & Spalding ITC-Focused Atty
• Commerce Orders Duties On Korean Chemical Imports
• Abbott Beats 'Supersized' Investor Suit Over Formula Recall
• Abbott Wins 7th Circ. Fight Over Baby Formula Warning
• Va. Court Orders FDA To Reconsider Mifepristone Restrictions
• Insulin Pen Lawsuit Against Novo Nordisk Headed For Trial
• 9th Circ. Revives Ex-Kaiser Worker's Vaccine Bias Suit
• Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win
• 'Irreparable': The Lasting Harm Of Justices' Temporary Orders
• Pet Medical Co. Sheds Dog Arthritis Drug Suit For Good
• Finch Therapeutics Can Seek Ch. 11 Plan Votes
• USPTO-Fed. Circ. Split Complicates Machine Learning Patents
• How 9th Circ. 'Shadow Trading' Case May Affect Private Credit
• Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads
• Fenwick, Latham Lead Scribe Therapeutics' $129M IPO
• Top Product Liability Cases Of 2026: Midyear Report
• CVS Seeks Toss Of Hospitals' 340B Suits In NY, Mich.
• Former Drug Co. Akorn Gets OK For $18.5M Ch. 7 Settlement
• Texas Panel Overturns Abortion Injunction Against Midwife
• AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says
• Abbott Labs Accused Of Lax Security Over Shinyhunters Hack
• Mo. Panel Says Exclusion Bars Mallinckrodt Opioid Coverage
• Kirkland, Sullivan & Cromwell Steer $2B ArisGlobal Deal
• Philly Judge Says Keller Postman Slowing Zantac Litigation
• AG Watch: Ohio AG Joins State Antitrust Enforcement Trend
• J&J's Delays Should End $25M Asbestos Appeal, Builder Says
• Being A Singer Makes Me A Better Lawyer
• J&J Talc Plaintiffs Must Back Up Cancer Link Or Risk MDL
• Late Emails Undercut BCBS Pricing Suit, Walgreens Says
• Organ Network, Hospital Sued Over Racial Kidney Criteria
• TransMedics Sheds Some Claims In Organ Transfer Biz Suit
• Boston Scientific Settles With Stryker In Spine Device IP Fight
• Mass. UHC Fraud Suit Signals States' Medicaid FCA Push
• FDA Draft Guidance Maps Payor Strategy For Psychedelics
• Safety-Net Clinics Defend Insulin Suit Revival To Justices
• Candid Health Wraps $120M Series D Funding Round
• Fed. Circ. Panel Stands By Invalidated Spinal Fusion IP
• 2 Charged In Alleged $52.7M COVID-19 Tax Scheme
• Squires Grants 4 IPRs, Issues No Discretionary Denials
• Goodwin, K&L Gates Steer $1.5B Repligen Gene Therapy Deal
• Judge Skeptical Of Harm From Chinese Military Co. Label
• Gene Therapy Co. Inks Better Ch. 11 Financing Deal
• How 2nd Circ. Raised The Bar For Pleading Securities Fraud
• DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief
• Trump Says 100% Tariff On Generic Drugs Coming In 2028
• DC Circ. Affirms HHS Authority Over 340B Rebate Plans
• Economist Concedes Opioid Stats' Limits In Albertsons Trial
• Full Fed. Circ. Won't Review Apple's ITC Loss Against Masimo
• Class Cert. In Avandia MDL Undone For Lacking Stats
• Invisalign Maker Align Keeps PTAB Wins At Fed. Circ.
• States Dispute Drugmakers' Bid To Toss GLP-1 Antitrust Case
• Thermo Fisher Says TRO Needed To Protect $8.9B Deal
• Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry
• Wyeth's Patent Loss Has Attys Focusing On Dosage
• Imaging Co. Faces Consolidated Data Breach Cases In NC
• Amgen To Pay $74M To End Investor Suit Over $10.7B Tax Bill
• CMS Withholds $1B In Medicaid From Calif., Minn., Citing Fraud
• Boehringer Alleges United Therapeutics Poached Staff, Secrets
• A&O Shearman Hires Davis Polk Restructuring Pro In NY
• Moderna Hits CureVac With Countersuit In COVID Vax Fight
• Albertsons Data Suggests Opioids Were Diverted, Expert Says
• Apple Can't Get Judge To Toss Masimo's $634M Patent Verdict
• SD Judge Blocks Abortion Ad Ban Against Atty, Nonprofit
• Latham, Cooley Steer $1.5B Tempus Cancer Testing Deal
• Quantifying Damages In Product Launch Delay Allegations
• Vanda's NDA Rejection Challenge Can't Be Heard At DC Court
• Trump Demands Review Of Judges' Science Manual
• 4 Patent Cases To Watch In The Second Half Of 2026
• Catching Up With Delaware's Chancery Court
• 3rd Circ. ERISA Ruling Stresses Process Over Perfect Returns
• Taylor Farms, Taco Bell Sued Over Cyclospora Outbreak
• US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine
• Ex-Hospital Exec Can't Cite Tainted Jury To Ditch Fraud Case
• Fed. Circ. Won't Review Reversal In $18M Penile Implant Case
• Md. Judge Stays Reforms Set To Shrink ACA Coverage Pool
• Drug Buyers' $62M Generic-Pricing Deal Gets Final OK
• Mass. Drug Co. To Pay $4.7M To Resolve Kickback Claims
• Fed. Circ. Licensing Rulings Shed Light On Patentee Standing
• Medical Groups Urge 1st Circ. To Back Vaccine Panel Freeze
• DaVita Wins Bid To Decertify 1,300-Member Collective
• Taxation With Representation: Freshfields, Slaughter And May
• The Biggest Trade Secret Rulings Of 2026: A Midyear Report
• UK Litigation Roundup: Here's What You Missed In London
• Commerce Opens Duty Probes Into Chinese Supplements
• FDA, Drugmakers Urge 5th Circ. To Allow Abortion Pill By Mail
• Pharma Co. Beats Investor Suit Over Prostate Drug Trial
• Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't
• DEA Judge Lays Out Next Steps Following End Of Pot Hearing
• Senate Democrats Revive Bill To End Federal Marijuana Ban
• Walgreens Sues Mass. Medicaid Program Over Drug Rates
• Fed. Circ. Vacates $12.7M Copyright Award Against Gov't
• Ropes & Gray, Latham Steer $3.8B Eli Lilly Mental Health Deal
• USTR Broadens Exemptions Ahead Of 25% Brazil Tariff
• Diagnostics Co. Labcorp Settles FCA Claims For $14.5M
• Being A Magician Makes Me A Better Lawyer
• Albertsons Slow To Review Wash. Opioid Sales, Judge Told
• Circuit-By-Circuit Guide To The US Supreme Court's Term
• Unilever Tangled In Litigation Again Over TRESemme
• Acorda Can't Add $66M To Award In Ampyra Royalty Fight
• Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug
• Braveheart Bio, Attovia Join Growing Pipeline Of Biotech IPOs
• Polsinelli, Doctor Seek Toss Of 'Bad Faith' Patent Claims
• What To Watch In Massachusetts In The 2nd Half Of 2026
• Squires Grants 10 PTAB Petitions, Denies 14 In Newest Order
• 9th Circ. Won't Revive Flea, Tick Meds Suit Against Bayer
• Covidien Hid Mesh Risk From Doctors, Bellwether Jury Told
• Glenmark Reaches $29M Deal In Generics Price-Fixing Case
• WilmerHale Adds Drug Pricing Regulatory Expert In Denver
• Albertsons Probed On Pharmacy Compliance Staffing At Trial
• Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech
• Patent Eligibility Bill Divides Senators Over Health Costs
• Bayer Defends Fees For Seed Tech With Expired Patents
• Judge Says Vanda-FDA Appointments Fight Likely Ripe
• Medical Device Co. Settles FCA Claims
• CVS Caremark Settles Out Of FTC Suit Over Insulin Pricing
• Google Is Wrong, 'Settled Expectations' Is Legal, Justices Told
• Cayman Judge Orders VC Apple Tree's Management Removed
• Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says
• Top Enviro Policy Developments From The First Half Of 2026
• How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom
• Goodwin Adds Life Sciences Veteran For San Diego Relaunch
• AI Drug Discovery Biz Valued At $3.8B After Series C Round
• BakerHostetler Flips Holland & Knight's Antitrust Co-Lead
• States Will Get $18M From 23andMe Ch. 11 For Data Breach
• Pharma Cos. Clash In Del. Chancery Over Dental Drug License
• Albertsons, Safeway Face Trial Over Wash.'s Opioid Epidemic
• 2nd Circ. Says Tylenol Maker Must Face Autism, ADHD Suits
• FTC Secures $12M Settlement Over Edwards-JC Medical Deal
• CVS Toddler Wipes Mislabeled As Hypoallergenic, Suit Says
• 7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block
• 23andMe Bankruptcy Plan Bars Data Breach Suit In Calif.
• Assertio Beats Investor Suit Over Drug, Merger Claims
• Families Cite Geofence Ruling In Newborn Blood Testing Case
• Catching Up With Delaware's Chancery Court
• Health Org. Can't Halt FTC Texas Suit Over Trans Youth Care
• Thermo Fisher Looks To Block Former Exec's Move To Fortrea
• Chemours Says NC Resident's PFAS 'Equity Action' Must Fail
• DOJ Appeals Order Shielding Trans Youth Medical Records
• Medical Device Co. Hit With Action Over Data Breach
• What Data Says About Biologics-Related Ex Parte Challenges
• Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case
• Boston Scientific Top Brass Sued Over Pacemaker Recall
• Ex-Biomedical Worker Axed For Not Altering Data, Suit Says
• 4 Firms Advise On $3.4B Apollo, Bayer Contraceptives Deal
• NY AG Says 3M, DuPont Hid PFAS Risks For Years
• VSL Reaches $20M Deal Resolving Knockoff Probiotic Claims
• Judge Skeptical On Restraining Order In Affirming Care Case
• Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt
• Regeneron Cites Medtronic Ruling In Amgen Bundling Case
• Sandoz's Patent Loss Blocks Antitrust Suit, 4th Circ. Told
• FDA Moves Leave Peptides In A Legal Gray Zone
• Fed. Circ. Affirms AstraZeneca Win Over $107.5M Verdict
• Actavis Can't Escape State AG Generic Drug Claims
• Bass Fishing Makes Me A Better Lawyer
• Sam's Club Reaches Deal With Ex-Worker In Miscarriage Suit
• How Reincorporating In Texas May Alter Earnout Disputes
• The Most Talked-About Supreme Court Decisions Of 2026
• Jazz Patent Suit Over Xyrem Survives Dismissal In NJ
• AstraZeneca Employee Traded On Icosavax Deal, SEC Says
• Pa. Superior Court Upholds J&J Win In Talc Cancer Suit
• Formula-Maker Sued After Recall And Reports Of Sick Infants
• PBMs Fight Bid To Add Pharmacy Group To Price-Fixing Suit
• Sheppard Adds Transactional, IP Attys In Chicago And San Diego
• Coordinating Life Sciences IP Strategies In The US And EU
• What Durnell Ruling Means For Mo. Roundup Settlement
• Handa, Intas Face Patent Suits Over Exelixis Cancer Drug
• Biggest Rulings For Patent Attys In 2026: A Midyear Report
• 2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme
• Illinois Cases To Watch In 2026: Midyear Report
• Regeneron Ducks Amgen's Eylea Antitrust Counterclaims
• CEO Cops To Conspiracy In BigLaw Insider Trading Case
• Align's Invisalign Patents Are Infringed But Invalid, Jury Finds
• Unstable Ex-Pfizer Office Spurs Evacuations In Manhattan
• 23andMe's $47M Data Breach Deal Gets Bankruptcy Court OK
• Mayo Sacked Research Director For Flagging Flaws, Suit Says
• P&G Brushes Off Harm Of Toothpaste Ingredient, Suit Claims
• Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel
• 5th Circ. Again Nixes Challenge To La. 340B Drug Delivery Law
• Fed. Circ. Won't Revive Dental Patent Claims In Align Feud
• Longtime Goodwin Procter IP Lawyer Moves To Pillsbury In DC
• CVS To Pay $36.5M To Settle States' Insulin FCA Suits
• 3 Firms Guide Vertex's $10B Buy Of Crinetics Pharmaceuticals
• 5,000 Pharmacies Accuse Prime Therapeutics Of Price-Fixing
• Medtronic Denied Bid To Nix $382M Antitrust Loss
• Clarivate Sells Life Sciences And Healthcare Biz For $600M
• Latest Squires Order Accepts 9 Patent Petitions, Rejects 2
• 3M, Chubb Settle Suit Over Warming Device Defense Coverage
• DOJ Urges DC Circ. Not To Freeze Medical Pot Rescheduling
• NC Biz Court Bulletin: Rapid-Fire Rulings, Word Of Warning
• Why Biotech Cos. Need Litigation Plans Before Bad News
• After Tense Terms, Hints Of High Court Harmony With Circuits
• The Moments That Shaped The Monsanto Decision
• The Funniest Moments Of The Supreme Court's Term
• Diagnostic Co.'s Oversight Reforms Deal Gets Final OK
• Illumina Looks To Duck DNA Rival's Renewed Antitrust Case
• 10 Years, 150 Cases: The Rise And Fall Of Post-Halo Damages
• Edwards Lifesciences Investors Seek 1st OK For $39M Deal
• Catching Up With Delaware's Chancery Court
• The Firms That Won Big At The Supreme Court
• The Sharpest Dissents From The Supreme Court Term
• The Year Donald Trump Won Big At The High Court
• Pharma CEO, Daughter To Pay $2M In SEC Stock Fraud Case
• Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review
• DOJ Has 'Negligible Interest' In Trans Patient Info, Judge Says
• Cox, Hikma Rulings Set Stage For Trademark Liability Fights
• Insulet Investor Says Device Production Issues Tanked Stock
• Fed. Circ. Won't Restore Doctor's Intubation Patent Suit
• Sinclair Convinces Ga. Panel To Sink Doctor's Defamation Suit
• Chubb, Lloyd's Units Seek Further Win Against Opioid Suits
• Legal Risks Of Using AI To Screen Psychedelic Trial Patients
• Senate Dems Say OMB Rule Would Politicize Federal Grants
• United Therapeutics Buys Thymmune For Up To $300M
• Skadden Adds Mass Torts Litigator As Partner In Chicago
• Breaking Down The Vote: The High Court Term In Review
• After Durnell, Connecting Science And Causation Will Be Key
• CMS Proposes Cut To Hospitals' 340B Drug Reimbursements
• Product Liability Q2 Regulatory Roundup
• Choral Singing Makes Me A Better Lawyer
• Big Pharma Cos. Want 340B Drug Price FCA Suit Tossed
• 3 Federal Circuit Clashes To Watch In July
• Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says
• Gov't Officials Tout Unprecedented Healthcare Fraud Push
• Amgen Wins Order Blocking Colorado's Enbrel Price Cap
• LSD Treatment Trade Secrets Suit Fails For Lack Of Specifics
• 8th Circ. Keeps Missouri's 340B Contract Pharmacy Law Alive
• EPA Approves Controversial Pesticides For Agricultural Use
• Attorney Mental Health Is An Ethical Obligation In The AI Era
• Split Fed. Circ. Backs Block On Generic Of Otsuka Neuro Drug
• The Case For Using Final-Offer Damages Forms In IP Suits
• Mazie Slater Beats Benicar Fees Sanctions Row Discovery Bid
• Ipsen Buying Memo Therapeutics For Up To $800M
• Medical Marijuana Cos. Seek To Back DOJ In DC Circ.
• Hogan Lovells Cadwalader Sees 'Opportunity' In Boston